Copper and Zinc Levels in Myelodysplastic Syndrome Patients versus Healthy Subjects

Document Type : Research Articles


1 Department of Internal Medicine, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

2 Pathology and Stem Cells Research Center, Kerman University of Medical Science, Kerman, Iran.

3 Department of Internal Medicine, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.

4 Physiology Research Center ,Institute of Basic and Clinical physiology sciences ,Kerman University of Medical Sciences ,Kerman, Iran.

5 Department of Pathology, Kerman University of Medical Science, Kerman, Iran.


Background: Myelodysplastic syndrome (MDS) is a heterogeneous hematological disease and certain serum factors are assumed to be involved in its pathogenesis and progression. Given this, our aim was to comparatively investigate the copper, zinc, and iron levels in MDS patients and healthy individuals. Methods: This case-control study was conducted on 31 patients with MDS (according to the WHO criteria after investigating laboratory tests such as peripheral blood smear and bone marrow aspiration) attending Bahonar Hospital, Kerman, Iran, and 31 healthy subjects from 2016 to 2018. The levels of copper, ceruloplasmin, zinc, ferritin, and iron were compared between the two groups. Results: Among the MDS patients, five individuals (16.13%) had low serum copper level (mean: 67.8 ± 4.35 µg/dl). Serum copper level was 111.3 ± 27.7 and 138.3 ± 26.6 in case and control groups, respectively (P = 0.0001). The serum zinc level and bone marrow iron level were also significantly different between the two groups (P < 0.05). Conclusion: Overall, it can be concluded that because only a small proportion of the MDS patients enrolled in this study were found to have lower copper levels compared with the MDS patients population, further studies with a larger sample size and also clinical trials in MDS patients with serum zinc, and copper deficiency are recommended, and post-treatment hematological reassessment would also be beneficial to achieving more definitive results.


Main Subjects

Volume 21, Issue 1
January 2020
Pages 239-241
  • Receive Date: 19 October 2019
  • Revise Date: 23 November 2019
  • Accept Date: 19 December 2019
  • First Publish Date: 01 January 2020